Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: Correlation with clinicopathologic features in 48 patients

Shunichi Yanai, Shotaro Nakamura, Morishige Takeshita, Kouhei Fujita, Minako Hirahashi, Keisuke Kawasaki, Koichi Kurahara, Yuji Sakai, Takayuki Matsumoto

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: Chromosomal translocation t(14;18)(q32;q21) involving the immunoglobulin heavy chain gene (IGH) and the BCL2 gene (t[14;18][q32;q21]/IGH- BCL2) is present in 60% to 90% of nodal follicular lymphomas. To the authors' knowledge, the prevalence and clinical significance of this translocation have not been examined previously in gastrointestinal follicular lymphomas. METHODS: Clinicopathologic and molecular features were investigated in 48 patients who had gastrointestinal follicular lymphoma. The site of involvement was the duodenum in 54% of patients, the jejunum in 52%, the ileum in 52%, the stomach in 29%, and the colorectum in 15%. The presence of the t(14;18)/IGH-BCL2 translocation was detected by interphase fluorescence in situ hybridization. RESULTS: Treatment modalities included surgical resection (n=16), rituximab plus chemotherapy (n=13), rituximab alone (n=6), antibiotics (n=5), and watchful waiting (n=8). Complete remission (CR) of lymphoma was achieved in 31 patients (65%). The overall survival and event-free survival rates after 5 years were 93% and 68%, respectively. The t(14;18)/IGH-BCL2 was detected in 39 patients (81%). The involvement of multiple sites (69% vs 0%), manifestation of the lymphomatous polyposis type (72% vs 22%), and histologic grade 1 or 2 tumors (92% vs 56%) were more frequent in the t(14;18)-positive group than in the negative group. In addition, the CR rate was lower in the t(14;18)-positive group than in the negative group (56% vs 100%; P=.0179), and a trend was observed toward poorer event-free survival in the positive group (P=.089). CONCLUSIONS: The t(14;18)/IGH-BCL2 chromosomal translocation occurred frequently in gastrointestinal follicular lymphomas. The current results indicated that this translocation may be a predictor of an adverse clinical course.

Original languageEnglish
Pages (from-to)2467-2477
Number of pages11
JournalCancer
Volume117
Issue number11
DOIs
Publication statusPublished - Jun 1 2011

Fingerprint

Follicular Lymphoma
Genetic Translocation
Disease-Free Survival
Watchful Waiting
Immunoglobulin Heavy Chain Genes
Interphase
Jejunum
Fluorescence In Situ Hybridization
Ileum
Duodenum
Lymphoma
Stomach
Survival Rate
Anti-Bacterial Agents
Drug Therapy
Survival
Genes
Neoplasms
Rituximab
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yanai, S., Nakamura, S., Takeshita, M., Fujita, K., Hirahashi, M., Kawasaki, K., ... Matsumoto, T. (2011). Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: Correlation with clinicopathologic features in 48 patients. Cancer, 117(11), 2467-2477. https://doi.org/10.1002/cncr.25811

Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma : Correlation with clinicopathologic features in 48 patients. / Yanai, Shunichi; Nakamura, Shotaro; Takeshita, Morishige; Fujita, Kouhei; Hirahashi, Minako; Kawasaki, Keisuke; Kurahara, Koichi; Sakai, Yuji; Matsumoto, Takayuki.

In: Cancer, Vol. 117, No. 11, 01.06.2011, p. 2467-2477.

Research output: Contribution to journalArticle

Yanai, S, Nakamura, S, Takeshita, M, Fujita, K, Hirahashi, M, Kawasaki, K, Kurahara, K, Sakai, Y & Matsumoto, T 2011, 'Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: Correlation with clinicopathologic features in 48 patients', Cancer, vol. 117, no. 11, pp. 2467-2477. https://doi.org/10.1002/cncr.25811
Yanai, Shunichi ; Nakamura, Shotaro ; Takeshita, Morishige ; Fujita, Kouhei ; Hirahashi, Minako ; Kawasaki, Keisuke ; Kurahara, Koichi ; Sakai, Yuji ; Matsumoto, Takayuki. / Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma : Correlation with clinicopathologic features in 48 patients. In: Cancer. 2011 ; Vol. 117, No. 11. pp. 2467-2477.
@article{efbc8f1fd6954f9896c3b756d7c16d06,
title = "Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: Correlation with clinicopathologic features in 48 patients",
abstract = "BACKGROUND: Chromosomal translocation t(14;18)(q32;q21) involving the immunoglobulin heavy chain gene (IGH) and the BCL2 gene (t[14;18][q32;q21]/IGH- BCL2) is present in 60{\%} to 90{\%} of nodal follicular lymphomas. To the authors' knowledge, the prevalence and clinical significance of this translocation have not been examined previously in gastrointestinal follicular lymphomas. METHODS: Clinicopathologic and molecular features were investigated in 48 patients who had gastrointestinal follicular lymphoma. The site of involvement was the duodenum in 54{\%} of patients, the jejunum in 52{\%}, the ileum in 52{\%}, the stomach in 29{\%}, and the colorectum in 15{\%}. The presence of the t(14;18)/IGH-BCL2 translocation was detected by interphase fluorescence in situ hybridization. RESULTS: Treatment modalities included surgical resection (n=16), rituximab plus chemotherapy (n=13), rituximab alone (n=6), antibiotics (n=5), and watchful waiting (n=8). Complete remission (CR) of lymphoma was achieved in 31 patients (65{\%}). The overall survival and event-free survival rates after 5 years were 93{\%} and 68{\%}, respectively. The t(14;18)/IGH-BCL2 was detected in 39 patients (81{\%}). The involvement of multiple sites (69{\%} vs 0{\%}), manifestation of the lymphomatous polyposis type (72{\%} vs 22{\%}), and histologic grade 1 or 2 tumors (92{\%} vs 56{\%}) were more frequent in the t(14;18)-positive group than in the negative group. In addition, the CR rate was lower in the t(14;18)-positive group than in the negative group (56{\%} vs 100{\%}; P=.0179), and a trend was observed toward poorer event-free survival in the positive group (P=.089). CONCLUSIONS: The t(14;18)/IGH-BCL2 chromosomal translocation occurred frequently in gastrointestinal follicular lymphomas. The current results indicated that this translocation may be a predictor of an adverse clinical course.",
author = "Shunichi Yanai and Shotaro Nakamura and Morishige Takeshita and Kouhei Fujita and Minako Hirahashi and Keisuke Kawasaki and Koichi Kurahara and Yuji Sakai and Takayuki Matsumoto",
year = "2011",
month = "6",
day = "1",
doi = "10.1002/cncr.25811",
language = "English",
volume = "117",
pages = "2467--2477",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma

T2 - Correlation with clinicopathologic features in 48 patients

AU - Yanai, Shunichi

AU - Nakamura, Shotaro

AU - Takeshita, Morishige

AU - Fujita, Kouhei

AU - Hirahashi, Minako

AU - Kawasaki, Keisuke

AU - Kurahara, Koichi

AU - Sakai, Yuji

AU - Matsumoto, Takayuki

PY - 2011/6/1

Y1 - 2011/6/1

N2 - BACKGROUND: Chromosomal translocation t(14;18)(q32;q21) involving the immunoglobulin heavy chain gene (IGH) and the BCL2 gene (t[14;18][q32;q21]/IGH- BCL2) is present in 60% to 90% of nodal follicular lymphomas. To the authors' knowledge, the prevalence and clinical significance of this translocation have not been examined previously in gastrointestinal follicular lymphomas. METHODS: Clinicopathologic and molecular features were investigated in 48 patients who had gastrointestinal follicular lymphoma. The site of involvement was the duodenum in 54% of patients, the jejunum in 52%, the ileum in 52%, the stomach in 29%, and the colorectum in 15%. The presence of the t(14;18)/IGH-BCL2 translocation was detected by interphase fluorescence in situ hybridization. RESULTS: Treatment modalities included surgical resection (n=16), rituximab plus chemotherapy (n=13), rituximab alone (n=6), antibiotics (n=5), and watchful waiting (n=8). Complete remission (CR) of lymphoma was achieved in 31 patients (65%). The overall survival and event-free survival rates after 5 years were 93% and 68%, respectively. The t(14;18)/IGH-BCL2 was detected in 39 patients (81%). The involvement of multiple sites (69% vs 0%), manifestation of the lymphomatous polyposis type (72% vs 22%), and histologic grade 1 or 2 tumors (92% vs 56%) were more frequent in the t(14;18)-positive group than in the negative group. In addition, the CR rate was lower in the t(14;18)-positive group than in the negative group (56% vs 100%; P=.0179), and a trend was observed toward poorer event-free survival in the positive group (P=.089). CONCLUSIONS: The t(14;18)/IGH-BCL2 chromosomal translocation occurred frequently in gastrointestinal follicular lymphomas. The current results indicated that this translocation may be a predictor of an adverse clinical course.

AB - BACKGROUND: Chromosomal translocation t(14;18)(q32;q21) involving the immunoglobulin heavy chain gene (IGH) and the BCL2 gene (t[14;18][q32;q21]/IGH- BCL2) is present in 60% to 90% of nodal follicular lymphomas. To the authors' knowledge, the prevalence and clinical significance of this translocation have not been examined previously in gastrointestinal follicular lymphomas. METHODS: Clinicopathologic and molecular features were investigated in 48 patients who had gastrointestinal follicular lymphoma. The site of involvement was the duodenum in 54% of patients, the jejunum in 52%, the ileum in 52%, the stomach in 29%, and the colorectum in 15%. The presence of the t(14;18)/IGH-BCL2 translocation was detected by interphase fluorescence in situ hybridization. RESULTS: Treatment modalities included surgical resection (n=16), rituximab plus chemotherapy (n=13), rituximab alone (n=6), antibiotics (n=5), and watchful waiting (n=8). Complete remission (CR) of lymphoma was achieved in 31 patients (65%). The overall survival and event-free survival rates after 5 years were 93% and 68%, respectively. The t(14;18)/IGH-BCL2 was detected in 39 patients (81%). The involvement of multiple sites (69% vs 0%), manifestation of the lymphomatous polyposis type (72% vs 22%), and histologic grade 1 or 2 tumors (92% vs 56%) were more frequent in the t(14;18)-positive group than in the negative group. In addition, the CR rate was lower in the t(14;18)-positive group than in the negative group (56% vs 100%; P=.0179), and a trend was observed toward poorer event-free survival in the positive group (P=.089). CONCLUSIONS: The t(14;18)/IGH-BCL2 chromosomal translocation occurred frequently in gastrointestinal follicular lymphomas. The current results indicated that this translocation may be a predictor of an adverse clinical course.

UR - http://www.scopus.com/inward/record.url?scp=79958753890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958753890&partnerID=8YFLogxK

U2 - 10.1002/cncr.25811

DO - 10.1002/cncr.25811

M3 - Article

C2 - 24048795

AN - SCOPUS:79958753890

VL - 117

SP - 2467

EP - 2477

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -